【摘要】 目的:观察喘可治注射液联合布地奈德福莫特罗治疗慢性阻塞性肺疾病(COPD)的疗效。方法:120例COPD患者随机分为2组,观察组予布地奈德福莫特罗吸入同时肌注喘可治注射液,对照组单纯给予布地奈德福莫特罗吸入。治疗28 d,比较两组FEV1%预计值、FEV1/FVC、6 min步行距离(6MWD)等肺功能指标变化和急性加重次数,同时观察治疗期间两组药物不良反应的发生情况。结果:治疗后2组肺功能和6 MWD均较前改善;观察组比对照组FEV1%预计值改善更明显[(59.7±12.1)%和(49.8±11.3)%,P<0.05],至少有1次急性加重的患者数明显减少(35%和62%,P<0.01),并且两组的药品不良反应发生率差异无统计学意义。结论:喘可治注射液联合布地奈德福莫特罗比单用布地奈德福莫特罗能更好地改善COPD患者的肺功能,减少急性加重次数,不会增加药品的不良反应发生率。更多还原

【Abstract】 Objective: To observe the efficacy of Chuankezhi injection combined with budesonide and formoterol fumarate powder for inhalation in the treatment of chronic obstructive pulmonary disease( COPD). Methods: Totally 120 patients with COPD were randomly divided into two groups: the observation group inhaled budesonide and formoterol fumarate powder for inhalation combined with intramuscular injection of Chuankezhi injection,and the control group inhaled budesonide and formoterol fumarate powder for inhalation. The treatment course was 28 days. The pulmonary function indices [FEV1% expected value,FEV1 / FVC,6 min walking distance( 6MWD) ],the times of acute exacerbation and the adverse drug reactions during the treatment were observed and compared between the two groups. Results: After the treatment,the lung function and 6MWD were improved in the two groups,and the improvement of FEV1% expected value in the treatment group was more obvious than that in the control group [( 59. 7 + 12. 1) % vs( 49. 8 +11. 3) %,P < 0. 05]. The number of patients with at least once of acute exacerbation was significantly reduced in the treatment group when compared with that in the control group( 35% vs 62%,P < 0. 01). The incidence of adverse drug reactions in the two groups showed no significant difference. Conclusion: Chuankezhi injection combined with budesonide and formoterol fumarate powder for inhalation can notably improve the lung function in the patients with COPD and reduce the times of acute exacerbation without effect on the incidence of adverse drug reactions.更多还原